unicar02-t
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 10, 2020 (NCT04230265)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04633148 | Phase 1 | Nov 16, 2020 | Cellex Patient Treatment GmbH, Institut fur Klinische Forschung, Germany, Julius-Maximilians University |
| NCT04230265 | Phase 1 | Jan 10, 2020 | Cellex Patient Treatment GmbH, Institut fur Klinische Forschung, Germany, Technical University of Dresden |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellex Patient Treatment GmbH | For profit | 2 | 2 | 1 | 2020 |
| Institut fur Klinische Forschung, Germany | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Julius-Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Technical University of Dresden | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1